Literature DB >> 32894820

Radiation oncology during COVID-19: Strategies to avoid compromised care.

Patrick J Horsley1, Michael Back1,2, Gillian Lamoury1, Brian Porter1, Jeremy Booth1,3, Thomas N Eade1.   

Abstract

The COVID-19 pandemic will present a range of challenges to radiation oncology departments. Early data suggest that cancer patients carry a higher than average, but still low absolute risk of hospitalization from COVID-19. The risk of severe events for those who are hospitalized however, is high. Resources for usual cancer care will likely be limited. Decisions to alter, delay or omit treatment during this period should consider both the risk of the cancer and of COVID-19 to the patient, as well as resource constraints. There is a need for departments to adapt with goals of maintaining an uninterrupted, high quality service and of minimizing compromise to oncologic care.
© 2020 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cancer; radiation oncology; radiotherapy

Mesh:

Year:  2020        PMID: 32894820     DOI: 10.1111/ajco.13456

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  3 in total

1.  Victoria (Australia) radiotherapy response to working through the first and second wave of COVID-19: Strategies and staffing.

Authors:  Kym Rykers; Mark Tacey; Jack Bowes; Kerryn Brown; Eva Yuen; Carlene Wilson; Richard Khor; Farshad Foroudi
Journal:  J Med Imaging Radiat Oncol       Date:  2021-04-27       Impact factor: 1.735

Review 2.  Covid-19 and radiotherapy: a systematic review after 2 years of pandemic.

Authors:  Antonio Piras; Valeria Venuti; Andrea D'Aviero; Davide Cusumano; Stefano Pergolizzi; Antonino Daidone; Luca Boldrini
Journal:  Clin Transl Imaging       Date:  2022-07-23

3.  Coronavirus disease 2019 (COVID-19) in patients before, during, or after lung irradiation, and serum SP-A and SP-D levels.

Authors:  Naoya Ishibashi; Toshiya Maebayashi; Takuya Aizawa; Masakuni Sakaguchi; Masahiro Okada
Journal:  Thorac Cancer       Date:  2022-09-30       Impact factor: 3.223

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.